{"id":"NCT01073293","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)","officialTitle":"A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04-22","primaryCompletion":"2011-06-16","completion":"2011-06-16","firstPosted":"2010-02-23","resultsPosted":"2014-12-22","lastUpdate":"2018-11-27"},"enrollment":1054,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Papillomavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V503 Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"REPEVAX™ (Concomitant)","otherNames":[]},{"type":"BIOLOGICAL","name":"REPEVAX™ (Non-concomitant)","otherNames":[]}],"arms":[{"label":"Concomitant Vaccination","type":"EXPERIMENTAL"},{"label":"Non-concomitant Vaccination","type":"EXPERIMENTAL"}],"summary":"This study will evaluate whether co-administration of the first dose of V503 and REPEVAX™ is well tolerated and causes a non-inferior immune response when compared to administration of REPEVAX™ one month following the first dose of V503.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503","timeFrame":"4 weeks following Month 6 vaccination","effectByArm":[{"arm":"Concomitant Vaccination","deltaMin":1637.9,"sd":null},{"arm":"Non-concomitant Vaccination","deltaMin":1725,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":23},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25831420","27422279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":525},"commonTop":["Injection-site pain","Injection-site swelling","Injection-site erythema","Headache","Pyrexia"]}}